Seller record · Telehealth service

Breeze Meds

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S4, compounding disclosure: No text states that the drugs sold are compounded or that compounded drugs lack Food and Drug Administration approval. The word compounded is printed only inside the artwork on five of seven product vial images, and the letters FDA appear nowhere in the text of the site's two live pages. 1 more criterion also fails; see the table below.

At a glance

Breeze MedsTelehealth service

6/8criteria passed
Price
From $100 for sermorelin to $399 for tirzepatide
Sells
semaglutide injection, tirzepatide injection, oral semaglutide, and 4 more
FDA letters
None on file
Visit Breeze MedsSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling weekly GLP-1 injections, oral semaglutide and tirzepatide, sermorelin and NAD+. Its privacy policy names Breezemeds, LLC and its footer names Breezemeds, Inc., and the two are reconciled nowhere on the site.

Operating entity Breezemeds, LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSBreeze Meds' website
S2Prescription gatingPASSBreeze Meds' consultation page
S3Pharmacy identificationPASSBreeze Meds' website
S4Compounding disclosureFAILBreeze Meds' website
S5Analytical documentationFAILBreeze Meds' website
S6Business addressPASSBreeze Meds' website
S7Price disclosurePASSBreeze Meds' website
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSTwo physicians are named with National Provider Identifier numbers, and the published three-step process puts a medical consultation before delivery. The site calls its providers nationwide rather than United States licensed.Source: Breeze Meds' website.
S2PASSEligibility questions gate the order. The intake runs ten screens from weight-loss goals to a contraindication screen naming pancreatitis and medullary thyroid carcinoma, and no price or payment screen appears in any of them.Source: Breeze Meds' consultation page.
S3PASSFour filling pharmacies are named with telephone numbers and web addresses: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx. No street address is printed for any of the four.Source: Breeze Meds' website.
S4FAILNo text states that the drugs sold are compounded or that compounded drugs lack Food and Drug Administration approval. The word compounded is printed only inside the artwork on five of seven product vial images, and the letters FDA appear nowhere in the text of the site's two live pages.Source: Breeze Meds' website.
S5FAILNo certificate, lot number, batch record or purity figure appears on either of the site's two live pages.Source: Breeze Meds' website.
S6PASSThe privacy policy, published as a panel on the homepage rather than as its own route, prints a street address on South Avenue SE in Marietta, Georgia, beside the operating company name and a support address.Source: Breeze Meds' website.
S7PASSSeven prices are printed on the public homepage before intake, from 100 dollars for sermorelin to 399 dollars for tirzepatide. Six of the seven state a dosing frequency and no billing period, and only the calculator card states a month.Source: Breeze Meds' website.
S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide injection, tirzepatide injection, oral semaglutide, oral tirzepatide, sermorelin, NAD+ injection, NAD+ nasal spray.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+

Visit Breeze Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.